Trade Names:Demerol- Tablets 50 mg- Tablets 100 mg- Syrup 50 mg/5 mL- Injection 25 mg/mL- Injection 50 mg/mL- Injection 75 mg/mL- Injection 100 mg/mL
Relieves pain by stimulating opiate receptors in CNS; also causes respiratory depression, peripheral vasodilation, inhibition of intestinal peristalsis, sphincter of Oddi spasm, stimulation of chemoreceptors that cause vomiting and increased bladder tone.
Meperidine protein binding is high.
The primary route for excretion is renal. The t ½ is 3 to 4 h.
Onset is 10 to 45 min.
The times to peak effect are 3 to 50 min (IM/Subcutaneous), 60 to 90 min (oral), and 5 to 7 min (IV).
Duration is 2 to 4 h.
Relief of moderate to severe pain.Parenteral
Preoperative sedation; support of anesthesia; obstetrical analgesia.
Upper airway obstruction; acute asthma; diarrhea due to poisoning or toxins; patients who are receiving or have received MAOI within last 14 days.
IM/Subcutaneous/PO 50 to 150 mg every 3 to 4 h as needed. If IV administration is required, reduce dose and administer slowly.Children
IM/Subcutaneous/PO 1 to 1.8 mg/kg (up to adult dose) every 3 to 4 h as needed.Preoperative SedationAdults
IM/Subcutaneous 50 to 100 mg 30 to 90 min before anesthetic.Children
IM/Subcutaneous 1 to 2 mg/kg (0.5 to 1 mg/lb), up to adult dose, 30 to 90 min before beginning anesthesia.Support of AnesthesiaAdults
IV Repeated doses diluted to 10 mg/mL by slow injection or by continuous infusion diluted to 1 mg/mL.Obstetrical AnalgesiaAdults
IM/Subcutaneous 50 to 100 mg every 1 to 3 h as needed when pains become regular.
Store at room temperature (59° to 86°F) in tightly closed, light-resistant container.
Additive CNS depression.Cimetidine
Monitor for increased respiratory and CNS depression.Hydantoins
Hydantoins may decrease the pharmacologic effects of meperidine, possibly because of increased hepatic metabolism of the narcotic.MAOIs, furazolidone
Potentially fatal reactions can occur if meperidine is used in patients within 14 days of receiving MAOI or furazolidone.Phenothiazines
Excessive sedation and hypotension.
Do not co-infuse with solutions of soluble barbiturates, aminophylline, heparin, morphine, methicillin, phenytoin, sodium bicarbonate, iodine, sulfadiazine and sulfisoxazole.
Increased amylase and lipase may occur up to 24 h after dose.
Hypotension; orthostatic hypotension; bradycardia; tachycardia.
Lightheadedness; dizziness; sedation; disorientation; incoordination; seizures.
Sweating; pruritus; urticaria.
Nausea; vomiting; constipation; abdominal pain.
Urinary retention or hesitancy.
Respiratory depression; laryngospasm; depression of cough reflex.
Pregnancy category undetermined. Safety not established.
Excreted in breast milk.
Dosage reduction may be necessary in patients with renal function impairment.
Dosage reduction may be necessary in patients with hepatic function impairment.
Use with caution in patients with myxedema, acute alcoholism, acute abdominal conditions, ulcerative colitis, decreased respiratory reserve, head injury or increased intracranial pressure, hypoxia, supraventricular tachycardia, depleted blood volume, circulatory shock or renal function impairment.
Some parenteral products contain sulfites; may cause allergic-type reactions in susceptible individuals.
Tolerance and psychological and physical dependence may occur with chronic use.
Can cause dysphoria, hallucinations and seizures in patients with renal function impairment or with chronic high-dose therapy.
Miosis, respiratory and CNS depression, circulatory collapse, seizures, cardiopulmonary arrest, death.
Copyright © 2009 Wolters Kluwer Health.